home / stock / azrx / azrx news

AZRX News and Press, AzurRx BioPharma Inc. From 01/06/20

Stock Information
Company Name: AzurRx BioPharma Inc.
Stock Symbol: AZRX
Market: NASDAQ
Website: azurrx.com
Menu
AZRX AZRX Quote AZRX Short AZRX News AZRX Articles AZRX Message Board
Get AZRX Alerts

News, Short Squeeze, Breakout and More Instantly...
AZRX - AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)

BROOKLYN, N.Y., Jan. 06, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company wil...
AZRX - AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer

NEW YORK, Jan. 03, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that Daniel Schneiderman...

AZRX - AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has entered into ...

AZRX - AzurRx BioPharma CEO Issues Letter to Shareholders

NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issued the following let...
AZRX - AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

Supports Company plan to proceed to higher 4-gram dose of MS1819-SD in next Phase 2 clinical trial No safety concerns cited for MS1819-SD NEW YORK, Oct. 17, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), ...

AZRX - AzurRx Bio launches mid-stage MS1819-SD study in combination with PERT

AzurRx BioPharma (NASDAQ: AZRX ) has dosed  first patients in its Phase 2 clinical trial to investigate MS1819-SD in combination with standard porcine enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF) who suffer from severe exocrine pancreatic insufficiency (EPI)...

AZRX - AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

First cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI) treated in dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme replacement therapy (PERT) Patients in study have persistent malnutrition and clinical symptoms o...
AZRX - AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer

NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, is pleased to announce that Jam...

AZRX - AzurRx Bio down 22% premarket on "positive" MS1819 data

Thinly traded nano cap AzurRx BioPharma (NASDAQ: AZRX ) slumps  22%  premarket on robust volume on the heels of "positive" data from a Phase 2 clinical trial, OPTION , evaluating lead candidate MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency , a d...

AZRX - AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients

Excellent safety results seen in CF patients, with CFA in line with previous studies and no need for a protease Management to discuss the results on a call scheduled for today, September 25, 2019 at 8:30 a.m. Eastern Time NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharm...
Previous 10 Next 10